<DOC>
	<DOC>NCT02108301</DOC>
	<brief_summary>The aim of the present trial is to evaluate whether the conversion of immunosuppression from tacrolimus to cyclosporine A induces changes in (i) hepatitis C-virus load, (ii) parameters of hepatic function and (iii) parameters of glucose tolerance in hepatitis C-positive renal transplant recipients.</brief_summary>
	<brief_title>Hepatitis C in Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>written informed consent prior renal transplantation current tacrolimusbased immunosuppressive regimen hepatitis Cinfection age 1870 years current hemodialysis or peritoneal dialysis pregnancy or breastfeeding known contraindication for cyclosporine Atreatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>chronic hepatitis C-virus infection</keyword>
	<keyword>renal transplantation</keyword>
	<keyword>glucose tolerance</keyword>
	<keyword>immunosuppression</keyword>
</DOC>